Bachem Holding
| BACHEM HOLDING AG
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | CH0012530207 |
| founding | 1971 |
| Seat |
Bubendorf BL , Switzerland
|
| management |
|
| Number of employees | 1140 |
| sales | 282.5 million CHF (2018) |
| Branch | Chemistry, biochemistry, pharmacy |
| Website | www.bachem.com |
| As of December 31, 2018 | |
The Bachem Holding AG is in the fields of chemistry , biochemistry and pharmaceutical active Swiss developed a technology company, which products and services for the pharmaceutical and biotechnology industries as well as -Research. Bachem specializes in the commercial production of peptides and complex organic compounds as active pharmaceutical ingredients, in the manufacture of peptide-based biochemicals and in the development of manufacturing processes for these compounds. The company was founded in 1971 and has its headquarters in Bubendorf in the canton of Basel-Landschaft in Switzerland. In addition to the Bubendorf site, Bachem has another large production site in Switzerland in Vionnaz in the canton of Valais . Further production sites are located in the USA in the Californian cities of Vista and Torrance and in Great Britain in St Helens near Liverpool . The sales and distribution location is also in Tokyo (Japan). As of the end of 2018, Bachem Holding AG employed 1,140 people worldwide, generated sales of CHF 282.5 million and a net profit of CHF 46.6 million.
history
In 1971 Peter Grogg founded the Bachem company with two employees. The company's headquarters were initially in Liestal near Basel , until the company with eight employees moved to nearby Bubendorf in 1977, where the company still has its headquarters today.
Group structure
Bachem Holding AG
The Bachem Group has had a holding structure since 2003 . The shares are listed on the Swiss Stock Exchange SWX Swiss Exchange under the symbol BANB listed . A majority of the shares are owned by company founder Peter Grogg.
Locations
From the headquarters in Bubendorf and the branches in Europe, the USA and Asia, Bachem works worldwide. Bachem Holding AG currently consists of the following six locations:
- Bubendorf , Switzerland: Headquarters of Bachem AG. Founded in 1971. Manufacture of peptides as active pharmaceutical ingredients and as chemicals for research .
- Vionnaz , Switzerland: Founded in 1973 and taken over by Bachem in 2001. Production of complex organic molecules as active pharmaceutical ingredients .
- St. Helens , Great Britain: Bachem UK Ltd. Founded in 1992 and taken over by Bachem in 1999. Manufacture of peptides as research chemicals and European competence center for immunological products.
- Torrance , California, USA: Bachem Americas, Inc. Founded in 1971 and acquired by Bachem in 1996. Manufacture of peptides as active pharmaceutical ingredients and as research chemicals. Founded in 2007: Sales company for all products of the Bachem groups in North, Central and South America.
- Vista , California, USA: Founded in 1987 and acquired in 2015 by Bachem's acquisition of the American Peptide Company. Development and manufacture of active pharmaceutical ingredients.
- Tokyo , Japan: Founded in June 2018 as a sales location and local presence for Bachem Holding AG in Japan and Asia.
business development
No business development figures are published for the period from the company's founding in 1971 to its IPO in 1998. In the year of the successful IPO in 1998, the Bachem Group's sales were CHF 96 million. By 2001, sales rose to CHF 141 million, also due to acquisitions. After a phase of stagnation up to 2004 (sales CHF 148 million), the group has since gone through a rather stormy, non-acquisition-related growth phase. In the years 2005 to 2007 well over 100 additional full-time positions and jobs were created. In Switzerland, the Bachem Group is also training 37 apprentices in various professions.
The share of sales generated in North America is 39.6% (2007). The rapid growth is primarily due to the growth in sales in the Active Pharmaceutical Ingredients division. The detailed figures on the business development of the Bachem Group are published in semi-annual and annual reports.
The Bachem Group (SIX: BANB) achieved record sales of CHF 282.5 million in 2018 with a net profit of CHF 46.6 million (+ 11.7% net profit compared to the previous year; + 79.6% compared to 2012 ). The operating result ( EBIT ) increased in 2018 by + 8.3% compared to 2017 to CHF 54.8 million (+ 58.0% compared to 2012). The EBITDA margin reached 27.6% and the EBIT margin 19.4%. Due to the good business situation and high capacity utilization, Bachem created a total of 39 new jobs by the end of 2018. As of December 31, 2018, the Bachem Group employed a total of 1140 people in 1097 full-time positions.
Business areas
Bachem's business activities are divided into the two business areas of research chemicals and active pharmaceutical ingredients .
The range of research chemicals includes amino acid derivatives , resins and reagents for peptide production and organic synthesis, bioactive peptides, enzyme substrates and other biochemicals. Bachem manufactures most of its products itself and sells them in a web shop in which several thousand products can be found. Custom research chemicals are manufactured as part of custom synthesis.
Customers for research chemicals are scientists at universities, hospitals and in research laboratories in the biotech and pharmaceutical industries.
In the Active Pharmaceutical Ingredients division, Bachem offers a large number of mostly peptide active ingredients that are used in clinical studies, in drugs approved for the market or, with increasing importance, in cosmetics. A distinction is made between patent-free ( generics ) and patent-protected ( New Chemical Entities , NCEs) for peptide active pharmaceutical ingredients . Typical examples of generic peptides are calcitonin , glucagon , gonadorelin , goserelin , leuprolide , somatostatin , octreotide , aviptadil , desmopressin , secretin , sincalid , thymosin , oxytocin , vasopressin .
The Bachem subsidiary in Vionnaz in the Swiss canton of Valais manufactures various non-peptide generic active ingredients, including the widely used short-term anesthetic propofol . In addition to such generic active ingredients, Bachem also offers process development and active pharmaceutical ingredients that are patented and that may only be manufactured and used by the originator or a partner commissioned by him. Most of the time, cooperation with regard to these active ingredients is subject to a confidentiality agreement. Many of these patent-backed products are still in clinical trials.
The active pharmaceutical ingredients manufactured by Bachem are used in a wide variety of therapeutic and diagnostic areas in human and veterinary medicine. Typical applications are found in the areas of cancer , osteoporosis , diabetes mellitus , Alzheimer's , bedwetting , hypoglycemia , with erectile dysfunction , the heart - circulation area or diseases of the gastrointestinal tract .
Customers for active pharmaceutical ingredients are biotechnology companies, pharmaceuticals and veterinary companies. Active ingredients contribute the largest share of the company's sales. Current figures can be found in the annual report published annually.
Individual evidence
- ↑ a b c d e f g h i j k Annual Report 2018 , accessed on August 8, 2019 (English)
- ↑ a b c d e bachem.com: Bachem - making history in peptide manufacturing for more than 40 years , accessed on February 11, 2017
- ↑ BACHEM shop. Retrieved August 15, 2019 .